Trial reportBMC primary care2026
Access to renal function information to improve pharmaceutical care in direct oral anticoagulant users: a cluster randomized trial protocol.
Trial report in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06739603 (Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDirect oral anticoagulants (DOACs) are commonly prescribed for the management of thromboembolic diseases and are known to increase the risk of bleeding. Renal impairment is a risk factor for bleeding in DOACs users, making renal function access essential for community pharmacists during the prescription review and dispensing process. However, community pharmacists often have limited access to patients' renal function information. Giving Community Pharmacists full access to the renal function information could help to mitigate this preventable part of the risk of bleeding by optimizing DOACs choice and dosage, thereby helping to reduce the risk of bleeding events. This study aims to assess the impact of providing Community Pharmacists with access to patients' renal function information when dispensing DOACs on the occurrence of clinically relevant bleeding events three months after dispensing.
methodsA prospective, comparative, randomized, cluster, multicenter trial involving 96 community pharmacies, allocated into two groups: intervention (systematic access to renal function) and control (usual care). A total of 1920 patients will be included over a 24-month period and followed for 6 months. The primary endpoint is the occurrence of clinically relevant bleeding-major and nonmajor-occurring within three months after DOACs dispensing. Secondary endpoints include detail of pharmacist interventions and an assessment of the feasibility of providing renal function access to Community Pharmacists. DISCUSSION: This study will assess the clinical impact of providing Community Pharmacists with access to renal function information. The findings have the potential to inform best practices and drive meaningful changes in ambulatory pharmaceutical care.
trial registrationThe trial is registered with ClinicalTrials.gov: NCT06739603, December 17th, 2024. https://clinicaltrials.gov/study/NCT06739603?term=NCT06739603&rank=1 .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.